533573 Stock Overview Develops, manufactures, and markets pharmaceutical products in India and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alembic Pharmaceuticals Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Alembic Pharmaceuticals Historical stock prices Current Share Price ₹1,055.00 52 Week High ₹1,296.15 52 Week Low ₹750.30 Beta 0.71 1 Month Change 1.19% 3 Month Change -5.41% 1 Year Change 36.41% 3 Year Change 37.33% 5 Year Change 86.73% Change since IPO 2,198.47%
Recent News & Updates
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18
Now 21% overvalued after recent price rise Oct 15 See more updates
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18
Now 21% overvalued after recent price rise Oct 15
Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg Oct 06
Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations Sep 16
Price target increased by 7.2% to ₹1,056 Sep 11
Investor sentiment improves as stock rises 17% Sep 10
Now 25% overvalued after recent price rise Sep 09
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12% Aug 24
Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal Aug 22
First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 09
Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 25
Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg Jul 24
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial Jul 12
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% Jul 09
Upcoming dividend of ₹11.00 per share Jul 08
Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg Jul 04
Now 21% overvalued Jul 01
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 25
Dividend increased to ₹11.00 Jun 24
Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024 Jun 10
Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business) Jun 08
Now 20% overvalued May 29
Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023) May 10 Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals
Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024 Apr 20
Price target increased by 8.4% to ₹933 Apr 12
Price target increased by 7.4% to ₹827 Feb 07
Third quarter 2024 earnings: Revenues in line with analyst expectations Feb 06
Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024 Jan 19
Investor sentiment improves as stock rises 17% Jan 15 Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality Dec 04
Alembic Pharmaceuticals Limited Announces Management Changes Nov 29
Alembic Pharmaceuticals Limited Announces Management Changes Nov 28
Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023 Oct 17
Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy Sep 02
Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel Aug 22
Price target increased by 10% to ₹659 Aug 07
First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023 Jul 24
Upcoming dividend of ₹8.00 per share at 1.2% yield Jul 21
Full year 2023 earnings: EPS exceeds analyst expectations Jun 24
Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023 Jun 06
Full year 2023 earnings: EPS exceeds analyst expectations May 06 Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director
Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022) Feb 04
Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes Feb 02
Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg Jan 20
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration Jan 07
Now 20% undervalued after recent price drop Dec 20
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05% Dec 11
Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w Dec 01
Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg Nov 21
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 16
Insufficient new directors Nov 16
Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg Nov 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 13
Investor sentiment improved over the past week Nov 03
Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G Nov 03
Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 02
Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration Oct 29
Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara Oct 27
Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022 Sep 16
Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg Aug 29
Upcoming dividend of ₹10.00 per share Aug 10
Price target decreased to ₹734 Aug 07
First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022 Jul 21
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Jun 22 Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg Jun 11
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Pirfenidone Tablets May 24
Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Arformoterol Tartrate Inhalation Solution, 15 Mcg (Base)/2 ML Unit-Dose Vial May 12
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 04
Insufficient new directors Apr 27
Alembic Pharmaceuticals Limited to Report Q4, 2022 Results on May 02, 2022 Apr 22
Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg Apr 20
Alembic Pharmaceuticals Limited Receives Tentative Approval from US Food & Drug Administration for Dabigatran Etexilate Capsules, 75 Mg, 110 Mg, and 150 Mg Apr 07
Alembic Pharmaceuticals Limited (NSEI:APLLTD) acquired remaining 40% stake in Aleor Dermaceuticals Limited from Orbicular Pharmaceutical Technologies Private Limited. Mar 31
Alembic Pharmaceuticals Limited (NSEI:APLLTD) acquired remaining 40% stake in Aleor Dermaceuticals Limited from Orbicular Pharmaceutical Technologies Private Limited. Mar 30
Alembic Pharmaceuticals Limited Appoints Ashok Barat as an Independent Director Feb 11
Third quarter 2022 earnings: EPS exceeds analyst expectations Feb 11 Alembic Pharmaceuticals Receives USFDA Final Approval for Clarithromycin Tablets Usp, 250 Mg and 500 Mg
Alembic Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022 Jan 28
Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg Jan 05 Alembic Pharmaceuticals Announces US FDA Tentative Approval for Dabigatran Etexilate Capsules, 150 Mg Alembic Pharmaceuticals Limited and Orbicular Pharmaceutical Technologies Private Limited Announce USFDA Final Approval for Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml Per Unit-Dose Vial
Second quarter 2022 earnings released: EPS ₹8.61 (vs ₹17.24 in 2Q 2021) Nov 11
Price target decreased to ₹950 Jul 28
First quarter 2022 earnings released: EPS ₹8.37 (vs ₹15.99 in 1Q 2021) Jul 27 Shareholder Returns 533573 IN Pharmaceuticals IN Market 7D -0.6% 1.8% -2.1% 1Y 36.4% 43.7% 22.5%
See full shareholder returns
Return vs Market: 533573 exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility Is 533573's price volatile compared to industry and market? 533573 volatility 533573 Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 533573 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 533573's weekly volatility (5%) has been stable over the past year.
About the Company Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products.
Show more Alembic Pharmaceuticals Limited Fundamentals Summary How do Alembic Pharmaceuticals's earnings and revenue compare to its market cap? 533573 fundamental statistics Market cap ₹205.96b Earnings (TTM ) ₹6.47b Revenue (TTM ) ₹63.57b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 533573 income statement (TTM ) Revenue ₹63.57b Cost of Revenue ₹17.44b Gross Profit ₹46.13b Other Expenses ₹39.66b Earnings ₹6.47b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 32.90 Gross Margin 72.56% Net Profit Margin 10.17% Debt/Equity Ratio 20.4%
How did 533573 perform over the long term?
See historical performance and comparison Dividends
1.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 17:06 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alembic Pharmaceuticals Limited is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sarabjit Nangra Angel Broking Private Limited null null Antique Stockbroking Ltd. Vijayaraghavan Swaminathan Avendus Spark
Show 23 more analysts 
